Rubius Therapeutics Overview
- Year Founded
-
2013

- Status
-
Out of Business
- Employees
-
6

- Latest Deal Type
-
Liquidation
Rubius Therapeutics General Information
Description
Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.
Contact Information
Website
www.rubiustx.comCorporate Office
- 399 Binney Street
- Suite 300
- Cambridge, MA 02139
- United States
Corporate Office
- 399 Binney Street
- Suite 300
- Cambridge, MA 02139
- United States
Rubius Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Bankruptcy: Liquidation | 06-Apr-2023 | Completed | Bankruptcy: Liquidation | |||
6. Debt Refinancing | 21-Dec-2018 | Completed | Pre-Clinical Trials | |||
5. IPO | 18-Jul-2018 | Completed | Pre-Clinical Trials | |||
4. Later Stage VC (Series C) | 01-Mar-2018 | Completed | Generating Revenue | |||
3. Early Stage VC (Series B) | 21-Jun-2017 | Completed | Generating Revenue | |||
2. Early Stage VC (Series A) | 27-Dec-2016 | $25M | $25M | Completed | Generating Revenue | |
1. Debt - General | 01-Nov-2015 | Completed | Generating Revenue |
Rubius Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C | ||||||||
Series B | ||||||||
Series A | 29,703,995 | $0.001000 | 8% | $0.6 | $0.6 | 1x | $0.6 | 39.94% |
Rubius Therapeutics Comparisons
Industry
Financing
Details
Rubius Therapeutics Competitors (21)
One of Rubius Therapeutics’s 21 competitors is PHAXIAM Therapeutics, a Formerly VC-backed company based in Lyon, France.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
PHAXIAM Therapeutics | Formerly VC-backed | Lyon, France | ||||
Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
American Gene Technologies | Venture Capital-Backed | Rockville, MD | ||||
Anokion | Venture Capital-Backed | Ecublens, Switzerland | ||||
Mustang Bio | Formerly VC-backed | Worcester, MA |
Rubius Therapeutics Patents
Rubius Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210246426-A1 | Engineered erythroid cells including hla-g polypeptides and methods of use thereof | Inactive | 10-Feb-2020 | ||
EP-4103696-A1 | Engineered erythroid cells including hla-g polypeptides and methods of use thereof | Inactive | 10-Feb-2020 | ||
US-20210147802-A1 | Methods of generating enucleated erythroid cells using taurine or hypotaurine | Inactive | 04-Nov-2019 | ||
US-20210130780-A1 | Methods of generating enucleated erythroid cells using myo-inositol | Inactive | 04-Nov-2019 | ||
AU-2020379755-A1 | Methods of generating enucleated erythroid cells using myo-inositol | Inactive | 04-Nov-2019 | C12N5/0641 |
Rubius Therapeutics Signals
Rubius Therapeutics Investments (2)
Rubius Therapeutics’s most recent deal was a Corporate Asset Purchase with 135,000-square foot manufacturing facility in Rhode Island for . The deal was made on 31-Jul-2018.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
135,000-square foot manufacturing facility in Rhode Island | 31-Jul-2018 | Corporate Asset Purchase | Buildings and Property | ||
100 Technology Way, Smithfield, Rhode Island | 01-Jul-2018 | Corporate Asset Purchase | Buildings and Property |
Rubius Therapeutics ESG
Risk Overview
Risk Rating
Updated October, 07, 2022
28.05 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,638
Rank
Percentile

Pharmaceuticals
Industry
of 1,008
Rank
Percentile

Biotechnology
Subindustry
of 465
Rank
Percentile

Rubius Therapeutics FAQs
-
When was Rubius Therapeutics founded?
Rubius Therapeutics was founded in 2013.
-
Where is Rubius Therapeutics headquartered?
Rubius Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Rubius Therapeutics?
Rubius Therapeutics has 6 total employees.
-
What industry is Rubius Therapeutics in?
Rubius Therapeutics’s primary industry is Drug Discovery.
-
Is Rubius Therapeutics a private or public company?
Rubius Therapeutics is a Private company.
-
What is Rubius Therapeutics’s current revenue?
The current revenue for Rubius Therapeutics is
. -
How much funding has Rubius Therapeutics raised over time?
Rubius Therapeutics has raised $562M.
-
Who are Rubius Therapeutics’s competitors?
PHAXIAM Therapeutics, Kite Pharma, American Gene Technologies, Anokion, and Mustang Bio are some of the 21 competitors of Rubius Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »